p90RSK2 is essential for FLT3-ITD- but dispensable for BCR-ABL-induced myeloid leukemia.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Blood

• Publication date

  2010-11-19

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1182/blood-2010-10-315721PMID 21527514PMCID PMC3128480
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• p 90 ribosomal S 6 kinase 2 promotes invasion and metastasis of human head and neck squamous cell carcinoma cells

  2010cited by this paper
• p90 ribosomal S6 kinase 2 promotes invasion and metastasis of human head and neck squamous cell carcinoma cells.

  2010cited by this paper
• betaTrCP- and Rsk1/2-mediated degradation of BimEL inhibits apoptosis.

  2009cited by this paper
• Fibroblast Growth Factor Receptor 3 Associates with and Tyrosine Phosphorylates p90 RSK2, Leading to RSK2 Activation That Mediates Hematopoietic Transformation

  2009cited by this paper
• Fibroblast growth factor receptor 1-transformed mammary epithelial cells are dependent on RSK activity for growth and survival.

  2009cited by this paper
• The RSK family of kinases: emerging roles in cellular signalling

  2008cited by this paper
• Critical role for Rsk2 in T-lymphocyte activation.

  2008cited by this paper
• Epidermal Growth Factor Stimulates RSK2 Activation through Activation of the MEK/ERK Pathway and Src-dependent Tyrosine Phosphorylation of RSK2 at Tyr-529*

  2008cited by this paper
• New insights into RSK activation and hematopoietic cancer.

  2007cited by this paper
• A clickable inhibitor reveals context-dependent autoactivation of p90 RSK.

  2007cited by this paper
• RSK2 Mediates Muscle Cell Differentiation through Regulation of NFAT3*

  2007cited by this paper
• Nur77 is phosphorylated in cells by RSK in response to mitogenic stimulation.

  2006cited by this paper
• FGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathway.

  2006cited by this paper
• Activation mechanisms of STAT5 by oncogenic Flt3-ITD.

  2006cited by this paper
• Recruitment of the Extracellular Signal-Regulated Kinase/Ribosomal S6 Kinase Signaling Pathway to the NFATc4 Transcription Activation Complex

  2005cited by this paper
• AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations.

  2005cited by this paper
• Structural Bioinformatics-Based Design of Selective, Irreversible Kinase Inhibitors

  2005cited by this paper
• p90Rsk is not involved in cytostatic factor arrest in mouse oocytes

  2005cited by this paper
• The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT.

  2005cited by this paper
• The serine/threonine protein kinase, p90 ribosomal S6 kinase, is an important regulator of prostate cancer cell proliferation.

  2005cited by this paper
• FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model.

  2005cited by this paper
• Essential role of RSK2 in c-Fos-dependent osteosarcoma development.

  2005cited by this paper
• Structural Bioinformatics-Based Design of Selective , Irreversible Kinase Inhibitors

  2005cited by this paper
• CHIR-258: A Potent Inhibitor of FLT3 Kinase in Experimental Tumor Xenograft Models of Human Acute Myelogenous Leukemia

  2005cited by this paper
• The tumor suppressor DAP kinase is a target of RSK-mediated survival signaling.

  2005cited by this paper
• In vivo Target Modulation and Biological Activity of CHIR-258, a Multitargeted Growth Factor Receptor Kinase Inhibitor, in Colon Cancer Models

  2005cited by this paper
• Constitutively activated FGFR3 mutants signal through PLCgamma-dependent and -independent pathways for hematopoietic transformation.

  2004cited by this paper
• ATF4 is a substrate of RSK2 and an essential regulator of osteoblast biology; implication for Coffin-Lowry Syndrome.

  2004cited by this paper
• Phosphorylation of p27Kip1 at Threonine 198 by p90 Ribosomal Protein S6 Kinases Promotes Its Binding to 14-3-3 and Cytoplasmic Localization*

  2003cited by this paper
• Arsenite-induced Phosphorylation of Histone H3 at Serine 10 Is Mediated by Akt1, Extracellular Signal-regulated Kinase 2, and p90 Ribosomal S6 Kinase 2 but Not Mitogen- and Stress-activated Protein Kinase 1*

  2003cited by this paper
• A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9

  2002cited by this paper
• The roles of FLT3 in hematopoiesis and leukemia.

  2002cited by this paper
• FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.

  2002cited by this paper
• Fusion of ETV6 to fibroblast growth factor receptor 3 in peripheral T-cell lymphoma with a t(4;12)(p16;p13) chromosomal translocation.

  2001cited by this paper
• C/EBPbeta phosphorylation by RSK creates a functional XEXD caspase inhibitory box critical for cell survival.

  2001influential reference
• Altered Extracellular Signal-Regulated Kinase Signaling and Glycogen Metabolism in Skeletal Muscle from p90 Ribosomal S6 Kinase 2 Knockout Mice

  2001cited by this paper
• Rsk1 mediates a MEK-MAP kinase cell survival signal.

  2000cited by this paper
• Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2.

  2000cited by this paper
• p90(RSK) is a serum-stimulated Na+/H+ exchanger isoform-1 kinase. Regulatory phosphorylation of serine 703 of Na+/H+ exchanger isoform-1.

  1999cited by this paper
• Role and regulation of 90 kDa ribosomal S6 kinase (RSK) in signal transduction.

  1999cited by this paper
• A p90(rsk) mutant constitutively interacting with MAP kinase uncouples MAP kinase from p34(cdc2)/cyclin B activation in Xenopus oocytes.

  1999cited by this paper
• Identification of Regulatory Phosphorylation Sites in Mitogen-activated Protein Kinase (MAPK)-activated Protein Kinase-1a/p90 rsk That Are Inducible by MAPK*

  1998cited by this paper
• Transformation of hematopoietic cell lines to growth‐factor independence and induction of a fatal myelo‐ and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes

  1998cited by this paper
• Evidence for two catalytically active kinase domains in pp90rsk

  1996cited by this paper
• Mutations in the kinase Rsk-2 associated with Coffin-Lowry syndrome

  1996cited by this paper
• Comparison of the specificities of p70 S6 kinase and MAPKAP kinase‐1 identifies a relatively specific substrate for p70 S6 kinase: the N‐terminal kinase domain of MAPKAP kinase‐1 is essential for peptide phosphorylation

  1995cited by this paper
• Signal transduction via the MAP kinases: proceed at your own RSK.

  1993influential reference
• Inactivation of glycogen synthase kinase-3 beta by phosphorylation: new kinase connections in insulin and growth-factor signalling.

  1993cited by this paper
• Insulin-stimulated MAP-2 kinase phosphorylates and activates ribosomal protein S6 kinase II

  1988cited by this paper
• A Xenopus ribosomal protein S6 kinase has two apparent kinase domains that are each similar to distinct protein kinases.

  1988cited by this paper
• : Structural

  year unknowncited by this paper

• Constitutive activation of the Src-family kinases Fgr and Hck enhances the tumor burden of acute myeloid leukemia cells in immunocompromised mice

  2025cites this paper
• Deletion of RSK2 kinase alleviates age-dependent hypertension

  2025cites this paper
• Discovery of 2,4-dianilinopyrimidine derivatives as novel p90 ribosomal S6 protein kinase (RSK) inhibitors.

  2025cites this paper
• Identification of RSK substrates using an analog-sensitive kinase approach

  2024cites this paper
• P90 ribosomal S6 kinases: a bona fide target for novel targeted anticancer therapies?

  2023cites this paper
• Combination of RSK inhibitor LJH-685 and FLT3 inhibitor FF-10101 promoted apoptosis and proliferation inhibition of AML cell lines

  2022cites this paper
• Theragnostic Strategies Harnessing the Self-Renewal Pathways of Stem-like Cells in the Acute Myeloid Leukemia.

  2022cites this paper
• Inference of kinase-signaling networks in human myeloid cell line models by Phosphoproteomics using kinase activity enrichment analysis (KAEA)

  2021cites this paper
• RSK Isoforms in Acute Myeloid Leukemia

  2021cites this paper
• RAF-MEK-ERK pathway in cancer evolution and treatment.

  2021cites this paper
• A systematic review of proteomic biomarkers in oral squamous cell cancer

  2021cites this paper
• Substituted pteridinones as p90 ribosomal S6 protein kinase (RSK) inhibitors: A structure-activity study.

  2020cites this paper
• Follistatin is a novel therapeutic target and biomarker in FLT3/ITD acute myeloid leukemia

  2020cites this paper
• Venetoclax and pegcrisantaspase for complex karyotype acute myeloid leukemia

  2020cites this paper
• RSK inhibitor BI-D1870 inhibits acute myeloid leukemia cell proliferation by targeting mitotic exit

  2020cites this paper
• The role of p90 ribosomal S6 kinases (RSKs) in Steroid signalling

  2019cites this paper
• A patent update on PDK1 inhibitors (2015-present)

  2019cites this paper
• FLT3-ITD Activates RSK1 to Enhance Proliferation and Survival of AML Cells by Activating mTORC1 and eIF4B Cooperatively with PIM or PI3K and by Inhibiting Bad and BIM

  2019influential citation
• RSK2 is a new Pim2 target with pro-survival functions in FLT3-ITD-positive acute myeloid leukemia

  2018cites this paper
• RSK2 contributes to myogenic vasoconstriction of resistance arteries by activating smooth muscle myosin and the Na+/H+ exchanger

  2018cites this paper
• Exploration of potential RSK2 inhibitors by pharmacophore modelling, structure-based 3D-QSAR, molecular docking study and molecular dynamics simulation

  2017cites this paper
• Luteolin, a novel p90 ribosomal S6 kinase inhibitor, suppresses proliferation and migration in leukemia cells.

  2017cites this paper
• Selective Targeting of RSK Isoforms in Cancer.

  2017cites this paper
• Defining the role of the RSK isoforms in cancer.

  2017cites this paper
• Bacterial Expression, Purification and In Vitro Phosphorylation of Full-Length Ribosomal S6 Kinase 2 (RSK2)

  2016cites this paper
• Ribosomal S6 kinase (RSK) modulators: a patent review

  2016influential citation
• RSK2[Ser227] at N-terminal kinase domain is a potential therapeutic target for multiple myeloma

  2013cites this paper
• Proteomics-based identification of plasma biomarkers in oral squamous cell carcinoma.

  2013cites this paper
• The p90 ribosomal S6 kinase (RSK) inhibitor BI-D1870 prevents gamma irradiation-induced apoptosis and mediates senescence via RSK- and p53-independent accumulation of p21WAF1/CIP1

  2013cites this paper
• The Prometastatic Ribosomal S6 Kinase 2-cAMP Response Element-binding Protein (RSK2-CREB) Signaling Pathway Up-regulates the Actin-binding Protein Fascin-1 to Promote Tumor Metastasis*

  2013cites this paper
• The unusual mechanism of inhibition of the p90 ribosomal S6 kinase (RSK) by flavonol rhamnosides.

  2013cites this paper
• Regulation of the kinase RSK1 by arsenic trioxide and generation of antileukemic responses

  2013cites this paper
• While at Rome miRNA and TRAIL Do Whatever BCR-ABL Commands to Do

  2013cites this paper
• Therapeutic Discovery RSK 2 Ser 227 at N-Terminal Kinase Domain Is a Potential Therapeutic Target for Multiple Myeloma

  2012cites this paper
• RSK2Ser227 at N-Terminal Kinase Domain Is a Potential Therapeutic Target for Multiple Myeloma

  2012cites this paper
• Targeting RSK2 in myeloid leukemia: Right for FLT3 but wrong for BCR-ABL

  2011cites this paper